Targeted biologics, the recent emergence of innovative new therapies, and the arrival of biosimilars will continue to fuel shifts in the way patients with psoriatic arthritis are managed. While the availability of multiple therapeutic tools has potential benefits for patients, deciphering which therapy is best for which patient, and when to switch therapies has its own challenges.
RealWorld Dynamix™: Biologic/Small Molecule Switching in PsA (US) will help you to understand the drivers of treatment switches in this volatile market. The study, which is the third annual wave, blends physician attitudes (“what they say”) with patient record data (“what they do”) to understand which products are positioned by the doctor in which patient. By analyzing only recent switches, real insights into prescribing behavior can be unearthed at the most dynamic end of the market. The resulting data set is a rich source of information and has multiple applications, including the quantitative definition of the winners and losers, by patient segment and recent therapy switches. As the third annual edition, the study will include switching trends from 2016 to present. This report will be an invaluable resource for addressing some of the key strategic issues and opportunities facing brands in the PsA space.
The report is based on a robust and deep patient chart analysis of ~1000 PsA patients who were switched from one biologic/Xeljanz or Otezla to a different brand in the past three months. Each physician completes an in-depth medical history of their last 3-7 patients who met the study inclusion criteria. An excellent augmentation to claims data, this study also captures the clinician’s perspective on why the switch was made and the new brand chosen, as well as future intentions should the response be suboptimal. In addition to patient demographics and treatment history, clinical assessments, diagnostic tests and laboratory values are included to provide insight into the clinical course of the disease.
This is the fifth annual edition of the report (fielded 2016-2020).
Learn more about RealWorld Dynamix™ reports here.
- Which products are benefitting and suffering from treatment switches?
- What role does the patient play in the switch decision?
- To what extent does market access influence brand choice when switching?
- How long are patients treated with an agent before a switch is made?
- What factors influence the switch decision and does this vary by patient segment?
- How will the introductions of Orencia, Taltz, and Xeljanz impact switching in PsA?
- How often do patients cycle through two TNFs before moving to an alternate MOA?
- How has the switching market changed over the past year?
- Where do pipeline agents like AbbVie’s upadacitinib and Janssen’s Tremfya have the most upside, if approved?
AbbVie (Humira), Amgen (Enbrel), BMS (Orencia), Celltrion/Pfizer (Inflectra), Celgene (Otezla), Eli Lilly (Taltz), Janssen (Remicade, Simponi, Stelara), Novartis (Cosentyx), Pfizer (Xeljanz), UCB Pharma (Cimzia)
AbbVie (Rinvoq, Skyrizi), BMS (BMS-986165), Gilead/Galapagos (filgotinib), Janssen (Tremfya), Ortho Dermatologics (Siliq), Sun Pharma (Ilumya), UCB (bimekizumab)